雅本化学(300261) - 2021 Q2 - 季度财报

Financial Performance - The company reported a revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 15%[25]. - The gross profit margin for the first half of 2021 was 35%, compared to 30% in the same period last year[25]. - The company's operating revenue for the reporting period was ¥1,158,526,705.60, representing a year-on-year increase of 25.07% compared to ¥926,313,159.19[32]. - The net profit attributable to shareholders was ¥105,032,597.23, an increase of 15.93% from ¥90,599,812.41 in the same period last year[32]. - The net profit after deducting non-recurring gains and losses was ¥84,775,075.83, showing a decrease of 22.38% compared to ¥109,216,831.49 from the previous year[32]. - The net cash flow from operating activities was ¥174,928,483.03, down 41.64% from ¥299,748,347.90 in the previous year[32]. - The total assets at the end of the reporting period were ¥3,957,983,305.41, a slight decrease of 0.14% from ¥3,963,340,487.18 at the end of the previous year[32]. - The net assets attributable to shareholders increased by 2.63% to ¥2,104,863,260.12 from ¥2,050,933,253.39 at the end of the previous year[32]. - The company achieved a revenue of 1,158.53 million CNY, representing a year-on-year growth of 25.07%[50]. - Net profit attributable to shareholders reached 105.03 million CNY, an increase of 15.93% compared to the previous year[50]. Research and Development - The company plans to invest RMB 50 million in R&D for new product development in the next fiscal year[25]. - R&D expenses amounted to 63.07 million CNY, accounting for 5.44% of total revenue, with a year-on-year increase of 36.55%[52]. - The company has applied for 7 invention patents during the reporting period, with a total of 148 authorized patents by the end of the period[52]. - The company is expanding its health business by developing a full industry chain from raw material R&D to brand marketing in dietary supplements[44]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share by 2023[25]. - User data indicates a 20% increase in customer base, reaching 10,000 active users by June 2021[25]. - The management has provided a performance guidance of 10-15% revenue growth for the second half of 2021[25]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[25]. Production and Capacity - A new production facility is set to be operational by Q4 2021, expected to increase production capacity by 25%[25]. - The company is expanding its production capacity at the new facility in Shangyu, which is expected to enhance its pharmaceutical and health product offerings[51]. - The company has launched over ten new health products, including NMN and Coenzyme Q10, to accelerate growth in the health sector[50]. Financial Management and Investments - The total amount of funds raised by the company was RMB 867,109,999.04, with a net amount of RMB 847,613,986.89 after deducting issuance fees[77]. - The company invested RMB 1,667.36 million of the raised funds during the reporting period, with a cumulative investment of RMB 69,585.76 million[75]. - The company reported a fair value change gain of RMB 19,652,554.84 for financial assets during the reporting period[73]. - The company has pledged 51% equity in Anyang Aierwang as collateral for a loan of RMB 41 million from Agricultural Bank of China[72]. Environmental Compliance - The company reported a total wastewater discharge of 4.3435 tons per year for COD, which is below the approved discharge limit of 15.847 tons per year[128]. - The company has one wastewater discharge point located in the southwest corner of the factory, with a COD concentration of 151 mg/L, compliant with local environmental standards[128]. - The company aims to maintain compliance with wastewater discharge standards, including COD ≤ 500 mg/L and BOD ≤ 300 mg/L[132]. - Future expansion plans include enhancing wastewater treatment capabilities to further reduce pollutant levels[134]. Risks and Challenges - The company faces risks related to raw material price fluctuations and has implemented measures to mitigate these risks[7]. - The company faces risks from macroeconomic changes, with potential adverse impacts on performance due to global economic fluctuations and the ongoing effects of the COVID-19 pandemic[114]. - Exchange rate fluctuations pose a risk to the company's export sales, and Yabont Chemical Co., Ltd. is implementing measures such as foreign exchange hedging to manage this risk[115]. Corporate Governance - The company has not distributed cash dividends or issued bonus shares for the reporting period[123]. - The semi-annual financial report has not been audited[150]. - The company has not undergone any bankruptcy restructuring during the reporting period[151]. - The company reported no significant litigation or arbitration matters during the reporting period[152].